Feng Chi Biotech

Feng Chi Biotech FCF per Share

The Free Cash Flow per Share of Feng Chi Biotech (6744.TWO) as of Nov 3, 2026 is -0.64 TWD. In the previous year, Free Cash Flow per Share was 0.68 TWD — a change of -194.62% (lower).

FCF per Share

-0.64TWD

YoY

-194.62%

Last updated:

Free Cash Flow per Share of Feng Chi Biotech is 2025 -0.64 TWD. Free Cash Flow per Share of Feng Chi Biotech was 2024 0.68 TWD. It decreases by -194.62% lower compared to the previous year.

The Feng Chi Biotech FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
2.86 TWD
Jan 1, 2019
1.28 TWD
Jan 1, 2020
2.34 TWD
Jan 1, 2021
2.06 TWD
Jan 1, 2022
1.82 TWD
Jan 1, 2023
0.91 TWD
Jan 1, 2024
0.68 TWD
Jan 1, 2025
-0.64 TWD
The Feng Chi Biotech FCF per Share history
YEARFCF per ShareYoY
-0.64TWD-194.62%
0.68TWD-25.25%
0.91TWD-50.28%
1.82TWD-11.61%
2.06TWD-12.13%
2.34TWD+83.01%
1.28TWD-55.27%
2.86TWD+508.31%
0.47TWD-70.92%
1.62TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Feng Chi Biotech Stock analysis

What does Feng Chi Biotech do? Feng Chi Biotech Corp. generates revenue through the sale of prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, and industrial microbiology and food testing reagents. The company's products are primarily sold to markets in Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, as well as other overseas regions. These services and products target healthcare providers, research institutions, and food safety regulators within these regions. The firm focuses on delivering comprehensive testing solutions across life science and microbiological applications for both clinical and industrial use cases. The company's product portfolio includes specialized reagents and instruments for prenatal and newborn screening, genetic analysis, and microbiological testing. These offerings are tailored to meet the needs of healthcare facilities and laboratories in the specified geographic markets. By providing end-to-end testing services and equipment, Feng Chi Biotech Corp. serves the growing demand for accurate diagnostic tools in reproductive health, genetic research, and food safety sectors. Feng Chi Biotech Corp. operates within the life science and microbiological testing services sector, offering a range of products that support prenatal care, neonatal screening, genetic research, and industrial food testing. The company's international sales strategy targets key regions in Asia, including Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, where healthcare and food safety regulations require regular testing. Their business model centers on providing reliable diagnostic solutions to medical and industrial clients across these markets. Feng Chi Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Feng Chi Biotech stock

Free Cash Flow per Share of Feng Chi Biotech is -0.64 TWD in 2025.

Free Cash Flow per Share of Feng Chi Biotech changed from 0.68 TWD to -0.64 TWD, representing a -194.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Feng Chi Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Feng Chi Biotech

All Key Metrics — Feng Chi Biotech